ReviewDiscover nano2026
Advances in drug delivery systems for Osteoarthritis therapy: exosomes, microparticles, nanoparticles, and hydrogels.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Osteoarthritis is a debilitating chronic joint disorder characterized by cartilage degradation, inflammation, and pain. It significantly impacts the quality of life, particularly in elderly populations. Traditional treatment methods, such as local and systemic drug administration, are limited by poor drug retention, low therapeutic efficacy, and systemic side effects. Recent advancements in drug delivery systems have emerged as promising strategies to overcome these limitations, offering targeted and sustained therapeutic effects, including promoting chondrocyte proliferation and migration, reducing extracellular matrix degradation, and so on. This review highlights the progress in various innovative drug delivery systems, including exosomes, microparticles, nanoparticles, and hydrogels, which have shown promising results in preclinical studies. Exosomes, particularly those derived from mesenchymal stem cells, demonstrate significant potential in promoting cartilage repair, modulating inflammation, and facilitating cell communication. Microparticles composed of natural or synthetic polymers prolong intra-articular drug retention and provide controlled release. Stimuli-responsive nanoparticles, which react to pathological cues like reactive oxygen species, pH, and enzymes, allow precise drug release within the OA microenvironment. Hydrogels offer versatile platforms for sustained delivery and tissue scaffolding, with responsive systems adapting to joint conditions. Despite their promising preclinical results, challenges remain in standardization, manufacturing scalability, and long-term safety. The continued development and clinical translation of these advanced systems hold great potential to revolutionize osteoarthritis therapy by improving efficacy, reducing side effects, and promoting joint tissue regeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.